Biotech · Private company
iCell Gene Therapeutics
Track this companyFree. Adds iCell Gene Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials42 recruiting or active
Pipeline programs1From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline1
- ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following lymphodepletionPhase 2 · Systemic Lupus Erythematosus (SLE)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus NephritisPHASE2 · RECRUITING · started Sep 1, 2026ClinicalTrials.gov NCT07328581 · fetched Nov 12, 2026
- Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell TransplantPHASE1 · SUSPENDED · started Mar 19, 2024ClinicalTrials.gov NCT06197672 · fetched Nov 12, 2026
- Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.PHASE1 · SUSPENDED · started Feb 21, 2024ClinicalTrials.gov NCT06071624 · fetched Nov 12, 2026
- CD4CAR for CD4+ Leukemia and LymphomaPHASE1 · RECRUITING · started Jul 9, 2020ClinicalTrials.gov NCT03829540 · fetched Nov 12, 2026